Michael S. Brown

CIK: 0001174475

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)1 (25.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

REGN

REGENERON PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

REGN
REGENERON PHARMACEUTICALS, INC.
Oct 30, 2026
Exercise(M)
Direct
1.9K shares at avg. $725.89$1.4M
REGN
REGENERON PHARMACEUTICALS, INC.
Oct 30, 2026
Sale(S)
Direct
1.9K shares at avg. $875.00$1.7M
REGN
REGENERON PHARMACEUTICALS, INC.
Jan 2, 2026
Award(A)
Direct
155 shares-
REGN
REGENERON PHARMACEUTICALS, INC.
Jan 2, 2025
Award(A)
Direct
166 shares-

		Type	Shares	Price		Ownership
Oct 30, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Exercise(M)	1,929	$725.89	$1,400,242	Direct
Oct 30, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Sale(S)	1,929	$875.00	$1,687,875	Direct
Jan 2, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Award(A)	155	-	$0	Direct
Jan 2, 2025	REGN REGENERON PHARMACEUTICALS, INC.	Award(A)	166	-	$0	Direct

1-4 of 4 transactions

About BROWN MICHAEL S

BROWN MICHAEL S (SEC CIK 0001174475) files insider reports with the SEC as Director of REGENERON PHARMACEUTICALS, INC. (REGN).

Signal8 holds 3 ownership filings by BROWN MICHAEL S, all Form 4s, filed between Jan 6, 2025 and Nov 3, 2026. Those filings report 4 transactions, from Jan 2, 2025 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BROWN MICHAEL S's filings is in TARRYTOWN, NY.

Recent filings by BROWN MICHAEL S

Oct 30, 2026: Option exercise of REGN shares (Form 4, code M).
Oct 30, 2026: Open-market sale of REGN shares (Form 4, code S).
Jan 2, 2026: Grant or award of REGN shares (Form 4, code A).
Jan 2, 2025: Grant or award of REGN shares (Form 4, code A).

Other insiders filing for REGENERON PHARMACEUTICALS, INC. (REGN)

Guarini Kathryn, Director
McCourt Marion, EVP Commercial
MURPHY ANDREW J, Co-Chief Scientific Officer
LAROSA JOSEPH J, EVP General Counsel and Secret
Fenimore Christopher R., EVP Finance CFO
Zoghbi Huda Y, Director

How to read Form 4 transaction codes